Jefferies analyst Biren Amin raised his price target for AnaptysBio (ANAB) to $145 after the company presented final data from its Phase IIa trial of ANB020 in 12 mod-to-severe adult atopic dermatitis patients. The shares closed Friday up $6.59, of 5.5%, to $126.45. Sustained efficacy on a single dose of '020 was seen up to day 78 at EASI-50 in 75% of patients, comparable to Phase II data from Sanofi (SNY) and Regeneron (REGN) competitor Dupixent, Amin tells investors in a research note. ANB020 beats if you account for single dose versus Q2 weeks of Dupi, the analyst contends. He keeps a Buy rating on AnaptysBio.

Leerink analyst David Risinger initiated coverage of AnaptysBio with an Outperform rating and $47 price target. The firm believes the company's R&D portfolio offers tremendous potential, shares are undervalued, and pipeline news flow is set to accelerate in late 2024-2025. AnaptysBio is an emerging I&I company with novel mechanisms for rheumatoid arthritis, ulcerative colitis, atopic dermatitis, and other immunological diseases. The company has two checkpoint agonists in Phase 2 development, and it plans to advance two additional novel mechanisms -- a CD122 antagonist and a BDCA2 modulator -- into the clinic this year. Leerink views the stock as undervalued even though it assigns conservative odds of success.